Cardiff Lexington Corporation (CDIX)
| Market Cap | 7.73M -92.1% |
| Revenue (ttm) | 10.84M +22.3% |
| Net Income | -9.21M |
| EPS | -0.99 |
| Shares Out | 15.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,500 |
| Open | 0.5800 |
| Previous Close | 0.5500 |
| Day's Range | 0.5060 - 0.5800 |
| 52-Week Range | 0.4000 - 14.2500 |
| Beta | 1.97 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Cardiff Lexington
Cardiff Lexington Corporation, through its subsidiaries, provides orthopedics, spine care, and pain management services in the United States. The company operates through two segments, Healthcare and Real Estate. The company provides diagnostic and surgical services for injuries and disorders of the skeletal system and associated bones, joints, tendons, muscles, ligaments, and nerves. It also engages in real estate business. The company also offers orthopedic and pain procedure services, including hip and knee replacement, shoulder reconstructi... [Read more]
Financial Performance
In 2025, Cardiff Lexington's revenue was $11.54 million, an increase of 39.48% compared to the previous year's $8.27 million. Losses were -$6.54 million, 53.4% more than in 2024.
Financial StatementsNews
Cardiff Lexington to Report Second Quarter 2026 Financial Results and Host Conference Call on Wednesday, August 12, 2026
LEXINGTON, KY / ACCESS Newswire / August 6, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management pl...
Cardiff Lexington Registration statement: Registration filing
Cardiff Lexington filed a registration statement on June 30, 2026, providing details about a securities offering with the SEC.
Cardiff Lexington Announces the Addition of Southeastern Surgery Center in Tallahassee, Florida to Nova Ortho and Spine Network
- Adds high visibility metropolitan location with potential for high patient volume - - 12th surgical center as company executes strategy to expand network throughout southeast and mid-Atlantic region...
Cardiff Lexington Registration statement: Registration filing
Cardiff Lexington filed a registration statement on June 24, 2026, providing details about a securities offering with the SEC.
Cardiff Lexington Registration statement: Registration filing
Cardiff Lexington filed a registration statement on June 11, 2026, providing details about a securities offering with the SEC.
Cardiff Lexington's Nova Ortho and Spine Announces New Medical Office in Stuart, Florida to Serve the Growing Treasure Coast Community
LEXINGTON, KY / ACCESS Newswire / May 20, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) ("Cardiff Lexington" or the "Company"), a publicly traded healthcare services holding company focused on ort...
Cardiff Lexington Announces First Quarter 2026 Financial Results
LEXINGTON, KY / ACCESS Newswire / May 19, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) today announced financial results for the first quarter ended March 31, 2026. Alex Cunningham, Chief Executi...
Cardiff Lexington Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined year-over-year due to fewer surgical procedures, but positive adjusted EBITDA was achieved. Working capital constraints and higher interest expenses impacted profitability, while expansion and M&A remain central to the growth strategy.
Cardiff Lexington Earnings release: Q1 2026
Cardiff Lexington released its Q1 2026 earnings on May 19, 2026, summarizing the period's financial results.
Cardiff Lexington Slides: Q1 2026
Cardiff Lexington has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 19, 2026.
Cardiff Lexington to Report First Quarter 2026 Financial Results and Host Conference Call on Tuesday, May 19, 2026
LEXINGTON, KY / ACCESS Newswire / May 14, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management plat...
Cardiff Lexington Corporation Announces Upgrade to OTCQX Best Market
LEXINGTON, KY / ACCESS Newswire / April 9, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) ("Cardiff Lexington" or the "Company"), a publicly traded healthcare services holding company focused on or...
Cardiff Lexington Announces Fourth Quarter and Full Year 2025 Financial Results
39.5% increase in FY25 total revenue to $11.5 million compared to FY 2024 62.7% increase in FY25 gross profit to $7.2 million compared to FY 2024 $1.1 million in income from continuing operations in F...
Cardiff Lexington Earnings Call Transcript: Q4 2025
Revenue grew 40% year-over-year to $11.5 million, driven by higher patient volume and expansion of Nova Ortho & Spine. Despite strong adjusted EBITDA, net loss widened due to increased interest expense from higher-cost capital used to fund growth.
Cardiff Lexington Slides: Q4 2025
Cardiff Lexington has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 16, 2026.
Cardiff Lexington Earnings release: Q4 2025
Cardiff Lexington released its Q4 2025 earnings on March 16, 2026, summarizing the period's financial results.
Cardiff Lexington To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Monday, March 16, 2026
LEXINGTON, KY / ACCESS Newswire / March 12, 2026 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced that the Company will host an investor conference call to discuss its financial and operat...
Cardiff Lexington Subsidiary Nova Ortho and Spine Announces New Healthcare Hires to Support Growth
LEXINGTON, KY / ACCESS Newswire / February 26, 2026 / Cardiff Lexington Corporation (OTCQB:CDIX), a healthcare holding company with deep leadership and operational expertise in Orthopedics, Spine Care...
Cardiff Lexington Corporation Engages Investment Bank to Lead S-1 Filing and Nasdaq Uplist Strategy
LEXINGTON, KY / ACCESS Newswire / January 20, 2026 / Cardiff Lexington Corporation (OTCQB:CDIXD) ("Cardiff" or the "Company"), a healthcare holding company with deep leadership and operational experti...
Cardiff Lexington Announces 1-for-3 Reverse Stock Split
LEXINGTON, KY / ACCESS Newswire / January 12, 2026 / Cardiff Lexington Corporation (OTCQB:CDIX) ("Cardiff" or the "Company"), a healthcare holding company with deep leadership and operational expertis...
Cardiff Lexington Announces Planned Retirement of Daniel Thompson as Chairman of the Board of Directors
- President and CEO of Cardiff Lexington, Alex Cunningham, to succeed Daniel Thompson as Chairman - LEXINGTON, KY / ACCESS Newswire / December 29, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX) ("C...
Cardiff Lexington Subsidiary Nova Ortho and Spine Performs First Procedures at Doctor's Memorial Hospital in Perry, Florida
LEXINGTON, KY / ACCESS Newswire / December 11, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX), a healthcare holding company with deep leadership and operational expertise in Orthopedics, Spine Care...
Cardiff Lexington Enters Advisory Agreement with Greentree Financial Group
LEXINGTON, KY / ACCESS Newswire / November 20, 2025 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced that it has entered into a new advisory agreement with Greentree Financial Group, Inc.,...
Cardiff Lexington Announces Third Quarter 2025 Financial Results
125.6% increase in total revenue to $3.1 million compared to 3Q24 437.8% increase in gross profit to $1.9 million compared to 3Q24 209.9% increase in income from continuing operations to $643,000 comp...
Cardiff Lexington Earnings Call Transcript: Q3 2025
Q3 2025 saw revenue surge 125.6% year-over-year to $3.1M, with gross margin rising to 62.4%. Growth is driven by Nova Ortho and Spine’s scalable model, high collection rates, and a robust M&A strategy targeting expansion in underserved markets.